Analysis of Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials - aVenture Research
BioSpace
Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials
Emalex Biosciences, Inc. ("Emalex"), a biopharmaceutical company founded to develop treatments for central nervous system movement disorders and fluency disorders, today announced $35 million in Series C Preferred Stock funding led by Paragon Biosciences. Fidelity Management & Research Company LLC and Valor Equity Partners joined the round.
An analysis reads this article and its sources, then explains what happened, who is involved, and what it means, quoting a source for each claim. Once written, every reader sees it here.
Analysis requires a paid plan or prepaid credits and uses your company research allowance.